ArticleCase reports in cardiology2025
Marked Sinus Bradycardia in a COVID-19 Patient.
Article in Case reports in cardiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Marked Sinus Bradycardia in a COVID-19 Patient.Case reports in cardiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The presence of cardiac manifestations, including bradycardia, has been described as a manifestation of coronavirus disease 2019 (COVID-19). Our case report describes a case of sinus bradycardia secondary to possible sinus node dysfunction in an otherwise asymptomatic patient with COVID-19. Case Presentation: We report the case of an unvaccinated 33-year-old female hospitalized due to bradycardia after 4 days of testing positive for COVID-19. She presented with a 1-day history of transitory lightheadedness and dizziness with no other associated symptoms. Sinus bradycardia was recorded on admission, heart rate 52/min that later dropped to 35/min on the second day of admission. Secondary causes of bradycardia were excluded based on the absence of relevant evidence from laboratory work-up and echocardiographic examination. Decision‐Making: We recommend baseline ECG monitoring in hospitalized COVID-19 patients, regardless of disease severity, to assess for potential cardiac manifestations. Conclusion: Cardiac rhythm monitoring is an essential component of staying vigilant against potential complications. It raises the question of how physicians should respond to a patient with marked bradycardia and when should they intervene?
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.